EP0119650A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Galactosyl-insulin conjugates useful in treating diabetics
Assignee: Procter and Gamble Co
•
Filing: 1984-03-08
•
Granted: —
•
Expires: 2004-03-08
Abstract
Abstract Biologically active galactosyl-insulin conjugates useful in the treatment of insulin-dependent diabetics, in particular diabetic humans are disclosed herein. The conjugates comprise at least one D-galactosyl group covalently bonded to insulin. The D-galactosyl group targets the conjugates to the hepatocytes. When these conjugates are administered to the diabetic, a more effective amount of insulin can be delivered to the liver for control of blood glucose levels.
Inventors
- 👤 David Vernon Myhre
- 👤 Walter Blair Geho
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-31 16:33
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/62; C07H; C07H3/00; C07H3/02; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
32 words
Galactosyl-insulin conjugates which are biologically active and are targeted to the liver, said conjugates being characterized in that they comprise: insulin; and at least one D-galactosyl group covalently bonded to said insulin.
Claim 2
Dependent Claim
32 words
Galactosyl-insulin conjugates which are biologically active and are targeted to the liver, said conjugates being characterized in that they comprise: insulin; and at least one D-galactosyl group covalently bonded to said insulin.
Claim 3
Dependent Claim
21 words
The conjugates of Claim 1 characterized in that said D-galactosyl group is selected from the group consisting of D-galactosyl and N-acetyl-D-galactosylamine.
Claim 4
Dependent Claim
46 words
The conjugates of any of Claims 1-2 characterized in that they have the general formula [Gal-Ll n -l wherein Gal is a D-galactosyl group; I is an insulin molecule; L is a linking group which covalently bonds Gal to I, and n is at least 1.
Claim 5
Dependent Claim
23 words
The conjugates of Claim 3 characterized in that Gal-L is an O-, S-, or N- D-galactosyl-glycoside, and n is from 1 to 3.
Claim 6
Dependent Claim
19 words
The conjugates of Claim 4 characterized in that D-galactosyl-glycoside is selected from the group consisting of lactobionyl and melibionyl.
Claim 7
Dependent Claim
16 words
The conjugates of any of Claims 3-5 characterized in that n is from 1 to 2.
Claim 8
Dependent Claim
29 words
A pharmaceutical composition for parenteral administration characterized in that it comprises the conjugates of any of Claims 1-6 and at least 99% by weight of a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.